Recognition and management of sleep-disordered breathing in chronic heart failure.
Recognition and management of sleep-disordered breathing in chronic heart failure.
复制标题
DOI：
10.1007/s11897-010-0037-1
复制
发表时间：
2011-03
影响因子：
--
通讯作者：
Khayat, Rami
中科院分区：
文献类型：
--
作者：
Kahwash, Rami;Kikta, Donald;Khayat, Rami
人们越来越认识到，睡眠呼吸障碍（SDB）是心血管疾病的常见可改变危险因素，对发病率和潜在死亡率有重大影响。 SDB 在收缩性或舒张性心力衰竭患者中非常常见。诊断心力衰竭患者的 SDB 时必须高度怀疑，因为绝大多数受影响的患者没有报告白天症状。最近的临床试验表明，心力衰竭患者接受 SDB 治疗后，心功能、运动耐量和生活质量均得到改善。越来越多的证据表明，SDB 的治疗应补充现有的慢性心力衰竭药物治疗。然而，死亡率方面的益处尚未得到证实。
It is increasingly recognized that sleep-disordered breathing (SDB) is a common modifiable risk factor for cardiovascular disease with significant impact on morbidity and potentially mortality. SDB is highly prevalent in patients with systolic or diastolic heart failure. A high index of suspicion is necessary to diagnose SDB in patients with heart failure because the vast majority of affected patients do not report daytime symptoms. Recent clinical trials have demonstrated improvement in heart function, exercise tolerance, and quality of life after treatment of SDB in patients with heart failure. Accumulating evidence suggests that treatment of SDB should complement the established pharmacologic therapy for chronic heart failure. However, mortality benefit has yet to be demonstrated.